Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sotera Health CoSHC +2.14%74 Debt-to-EBITDA is 5.25 as of Mar. 2026, which is 5% below its 10-year median of 5.52. GuruFocus rates SHC with a GF Score™ of 74/100 and a GF Value™ of $16.36 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 112 Medical Diagnostics & Research companies, Sotera Health Co ranks worse than 82.14% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sotera Health Co's Debt-to-EBITDA or its related term are showing as below:
SHC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -116.7 Med: 5.52 Max: 9.38
Current: 4.72
During the past 8 years, the highest Debt-to-EBITDA Ratio of Sotera Health Co was 9.38. The lowest was -116.70. And the median was 5.52.
SHC's Debt-to-EBITDA is ranked worse than 82.14% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.29
vs SHC: 4.72
Sotera Health Co (NAS:SHC) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sotera Health Co Debt-to-EBITDA Related Terms
Sotera Health Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sotera Health Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHC vs VCYT, RDNT, BLLN: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Sotera Health Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotera Health Co Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sotera Health Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Sotera Health Co (SHC) has a Debt-to-EBITDA of 5.25 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sotera Health Co. This is near median its historical median of 5.52. According to the industry distribution chart, Sotera Health Co ranks #92 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 82.1%.
Is Sotera Health Co's Debt-to-EBITDA too high?
Sotera Health Co's current Debt-to-EBITDA of 5.25 is near median its 10-year median of 5.52. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.29. Sotera Health Co's value of 5.25 is 129.3% above this industry median. Based on the distribution chart, Sotera Health Co ranks #92 out of 112 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Sotera Health Co has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's Debt-to-EBITDA compare to VCYT and RDNT?
According to the Medical Diagnostics & Research industry distribution chart, Sotera Health Co ranks #92 out of 112 companies for Debt-to-EBITDA. This places Sotera Health Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.29. Sotera Health Co's value of 5.25 is 129.3% above this benchmark. While the company's 10-year median is 5.52 vs. the industry median of 2.29, Sotera Health Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.29, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotera Health Co's current Debt-to-EBITDA of 5.25 is 129.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sotera Health Co. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotera Health Co's current Debt-to-EBITDA is 5.25, which is near median its own 10-year median of 5.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $16.36, compared to a current price of $18.15 — trading 10.9% above its estimated fair value. The current Debt-to-EBITDA is 5.25, which is near median its 10-year median of 5.52 and 129.3% above the Medical Diagnostics & Research industry median of 2.29. Sotera Health Co's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sotera Health Co (SHC), the current Debt-to-EBITDA is 5.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotera Health Co (SHC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued.
The current stock price of $18.15 is trading 10.9% above its estimated GF Value™ of $16.36.
GuruFocus considers Sotera Health Co to be Modestly Overvalued.
Key valuation signals for SHC:
Debt-to-EBITDA: 5.25 (near median its 10-year median of 5.52)
GF Value™: $16.36 vs. price of $18.15 (10.9% above fair value)
Industry Position: 129.3% above the Medical Diagnostics & Research median (#92 of 112)
No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
74GF Score
Get the complete analysis for SHC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHC has been successfully added to your 
